IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-34. (Canceled)

35. (New) A method of inhibiting HIV replication, said method comprising contacting a cell comprising HIV with an effective amount of a compound having the structure:



or



wherein

A is selected from the group consisting of N, CR_1, and 

;

B is selected from the group consisting of N and S;

Y is selected from the group consisting of Se, CH and CR_4;

X is selected from the group consisting of CH and N;

R_1 is selected from the group consisting of H, NR_5R_6 and



R_2 and R_3 are independently selected from the group consisting of H, halo, hydroxy and C_1-C_4 alkyl;

R_4 is selected from the group consisting of H, halo, hydroxy and C_1-C_4 alkyl;



R_5 and R_6 are independently selected from the group consisting of H and C_1-C_4 alkyl;

R_7 and R_8 are independently selected from the group consisting of H, halo, hydroxy, C_1-C_4 alkyl, C_1-C_4 alkoxy, -NHC(O)CH_3 and -O(C_1-C_4 alkyl)(C_5-C_6 heterocyclic) or R_7 and R_8 together with the atoms to which they are attached form an optionally substituted C_5-C_6 aryl, wherein the aryl ring is optionally substituted with halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkyl(C_5-C_6 aryl) and -O(C_1-C_4 alkyl)(C_5-C_6 heterocyclic). In one embodiment Y is CR_4, R_7 is H or C_1-C_4 alkoxy, R_8 is halo or



, wherein n is an integer ranging from 1-5, and P, W and Z are independently selected from the group consisting of O, S, CH_2 and NH;

further wherein said compound is selected from the group consisting of

103833:



3-amino-5-ethyl-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide,

AE-641/15124054 (311)



,

AE-848/11105217 (312)



,

(313)

AE-848/34405027



,

AG-205/08592044 (314)



,

AG-205/11781740 (315)



,

AG-205/31312022 (316)



,

AG-205/33137032 (317)



,

AG-205/33137032 (318)



,

AG-205/33139015 (319)



,

AG-205/33156001 (320)



,

AG-205/33684025 (321)



,

AG-205/36992106 (322)



,

AG-690/1370414 (323)



,

AG-690/34037018 (324)



,

AH-262/343350 (325)



,

AH-262/36083007 (326)



,

AK-777/115000 (327)



,

AK-777/36935027 (328)



,

AK-968/37156085 (329)



,

AM-807/12740245 (330)



,

AM-807/13614287 (331)



,

AM-807/14147906 (332)



,

AM-807/42004022 (333)



,

AM-807/42860050 (334)



AN-329/05740035 (335)



AN-919/14791006 (336)



,

AO-799/42008042 (337)



,

AO-799/43115183 (338)



,

and

(339)

AQ-750/42052143



.

36. (New) The method of claim 35, wherein said compound inhibits REV function.

37. (New) The method of claim 35, wherein HIV virion production is dependent on Rev protein expression.

38. (New) The method of claim 35, wherein said compound is 103833:



3-amino-5-ethyl-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide